96 related articles for article (PubMed ID: 7871580)
1. The role of anti-class II HLA antibodies in heart transplantation.
Nikaein A; Alivizatos PA; Monahan K; Stone MJ
Transplantation; 1995 Feb; 59(3):439-42. PubMed ID: 7871580
[No Abstract] [Full Text] [Related]
2. Positive effects of anti-T-cell monoclonal antibodies on rat allograft survival.
Claesson K; Larsson P; Holmdahl R; Klareskog L; Forsum U; Tufveson G
Transplant Proc; 1987 Feb; 19(1 Pt 1):615-6. PubMed ID: 3079163
[No Abstract] [Full Text] [Related]
3. Requirement for DR sharing in stable kidney allograft tolerance induced by donor bone marrow in rhesus monkeys.
Thomas J; Kasten-Jolly J; Verbanac K; Smith JP; Carver M; Gross U; Rebellato L; Thomas F; Haisch C
Transplant Proc; 1995 Feb; 27(1):686-8. PubMed ID: 7879146
[No Abstract] [Full Text] [Related]
4. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I.
Süsal C; Opelz G
Hum Immunol; 2004 Aug; 65(8):810-6. PubMed ID: 15336782
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
6. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
Rodríguez LM; París SC; Arbeláez M; Cotes JM; Süsal C; Torres Y; García LF
Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of HLA-DRB1 typing in cadaveric renal transplantation.
Kobayashi T; Negita M; Yokoyama I; Kamura H; Kohara S; Ohshima S; Fujita T; Ono Y; Kinukawa T; Hoshinaga K
Transplant Proc; 1993 Dec; 25(6):3271-2. PubMed ID: 8266538
[No Abstract] [Full Text] [Related]
8. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
[TBL] [Abstract][Full Text] [Related]
9. A reevaluation of the role of IgM Non-HLA antibodies in cardiac transplantation.
Smith JD; Hamour IM; Burke MM; Mahesh B; Stanford RE; Haj-Yahia S; Robinson DR; Kaul P; Yacoub MH; Banner NR; Rose ML
Transplantation; 2009 Mar; 87(6):864-71. PubMed ID: 19300190
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies?
Kaczmarek I; Deutsch MA; Rohrer ME; Beiras-Fernandez A; Groetzner J; Daebritz S; Schmoeckel M; Spannagl M; Meiser B; Reichart B
J Heart Lung Transplant; 2006 Sep; 25(9):1057-62. PubMed ID: 16962466
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional blockade of CD4 and major histocompatibility complex class II molecules: an effective immunosuppressive treatment in the mouse heart transplantation model.
Ito H; Hamano K; Fukumoto T; Wood KJ; Esato K
J Heart Lung Transplant; 1998 May; 17(5):460-9. PubMed ID: 9628564
[TBL] [Abstract][Full Text] [Related]
12. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome.
Di Filippo S; Girnita A; Webber SA; Tsao S; Boyle GJ; Miller SA; Gandhi SK; Zeevi A
Hum Immunol; 2005 May; 66(5):513-8. PubMed ID: 15935888
[TBL] [Abstract][Full Text] [Related]
13. Anti-idiotypic antibodies specific for HLA in heart and kidney allograft recipients.
Reed E; Ho E; Cohen DJ; Ramey W; Marboe C; D'Agati V; Rose EA; Hardy M; Suciu-Foca N
Immunol Res; 1993; 12(1):1-11. PubMed ID: 8515181
[TBL] [Abstract][Full Text] [Related]
14. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts.
Barr ML; Cohen DJ; Benvenisty AI; Hardy M; Reemtsma K; Rose EA; Marboe CC; D'Agati V; Suciu-Foca N; Reed E
Transplant Proc; 1993 Feb; 25(1 Pt 1):262-4. PubMed ID: 8438294
[TBL] [Abstract][Full Text] [Related]
15. Alloantibodies in heart transplantation.
Ho EK; Vlad G; Colovai AI; Vasilescu ER; Schwartz J; Sondermeijer H; Burke E; Marboe CC; Itescu S; Suciu-Foca N; Mancini D
Hum Immunol; 2009 Oct; 70(10):825-9. PubMed ID: 19555730
[TBL] [Abstract][Full Text] [Related]
16. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation.
Le Bas-Bernardet S; Hourmant M; Valentin N; Paitier C; Giral-Classe M; Curry S; Follea G; Soulillou JP; Bignon JD
Transplantation; 2003 Feb; 75(4):477-82. PubMed ID: 12605113
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte antigen class II antibodies and transplant outcome.
Duquesnoy RJ
Transplantation; 2008 Sep; 86(5):638-40. PubMed ID: 18791442
[No Abstract] [Full Text] [Related]
18. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels.
Issa N; Cosio FG; Gloor JM; Sethi S; Dean PG; Moore SB; DeGoey S; Stegall MD
Transplantation; 2008 Sep; 86(5):681-5. PubMed ID: 18791449
[TBL] [Abstract][Full Text] [Related]
19. The relationship of nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-HLA antibodies, and coronary artery disease following heart transplantation.
Chu KE; Ho EK; de la Torre L; Vasilescu ER; Marboe CC
Cardiovasc Pathol; 2005; 14(4):219-24. PubMed ID: 16009321
[TBL] [Abstract][Full Text] [Related]
20. Anti-HLA antibodies in heart transplantation.
Vasilescu ER; Ho EK; de la Torre L; Itescu S; Marboe C; Cortesini R; Suciu-Foca N; Mancini D
Transpl Immunol; 2004 Jan; 12(2):177-83. PubMed ID: 14967316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
